Interesting read, cheers. Same goes for the Ionis link from Hottod.
Gyroscope also has several additional assets in its pipeline in early discovery for retinal diseases.
Quite comparable to us as we near the final period prior to clinical on our first two ocular programs ( Gyrosscope was picked up prior to clinical stage as well on this one ), with all other ocular programs closely lined up and validated as management was pointing out the feed though application of success from the lead to all follow up oculars in the last update. Additionally, one would assume that kidney or CNS or something like a glaucoma application within the ocular platform is providing ample partial sale opportunities for the company to finance a speedy progress on lead programs to market.
It just shows how ridiculously undervalued the stock is currently We are below fair value for our lead program only at its current stage, ignoring entire pipeline
A large CNS deal in 2022 is still my assumption and current positioning and trading is the precursor
all IMO
PYC Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)